Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-melanoma Skin Cancer (NMSC): early-phase trial registry
2 of 4 indexed Non-melanoma Skin Cancer (NMSC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Non-melanoma Skin Cancer (NMSC): 4 US clinical trials tracked, 2 recruiting.
Non-melanoma Skin Cancer (NMSC) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Replimune, running 1 of these trials.
Enrollment posture brief
Registry condition non-melanoma-skin-cancer-nmsc
OPEN 2 | RECR 50% | LATE 0 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Non-melanoma Skin Cancer (NMSC) lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-melanoma Skin Cancer (NMSC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-melanoma Skin Cancer (NMSC) is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically
Dartmouth-Hitchcock Medical Center
NCT07201376
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
University of Utah
NCT04844528
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Replimune
NCT03767348
Interest and Impact of Skin Cancer Genetic Testing
Memorial Sloan Kettering Cancer Center
NCT02941900
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-melanoma Skin Cancer (NMSC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-melanoma Skin Cancer (NMSC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-melanoma Skin Cancer (NMSC) page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Non-melanoma Skin Cancer (NMSC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Replimune sponsors the most Non-melanoma Skin Cancer (NMSC) trials on record, review their full trial history before evaluating a specific study. See Replimune's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-melanoma Skin Cancer (NMSC) condition card totals 4 registered trials; most-linked intervention MC1R Testing Website; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.